文献速递妇科

绝经前女性因良性指征行手术绝经后雌激素替代治疗使用不足相关的超额疾病发生与死亡

Excess morbidity and mortality associated with underuse of estrogen replacement therapy in premenopausal women who undergo surgical menopause.
PubMed 文献 · Am J Obstet Gynecol · 2024-02-15

该研究采用两个贝叶斯抽样马尔可夫状态转移模型,估算45至49岁因良性指征行双侧卵巢切除术加子宫切除术后当前雌激素治疗模式相关的超额发病与死亡。与100%使用相比,25年后冠心病多658例、卒中多881例、乳腺癌死亡多189例、冠心病死亡多380例、其他原因死亡多759例。作者结论认为雌激素使用不足与大量超额发病和死亡相关。

要点

  • 模型模拟45至49岁因良性指征行双侧卵巢切除加子宫切除的女性,随访25年。
  • 与100%使用雌激素相比,25年后冠心病多658例、卒中多881例。
  • 与100%使用雌激素相比,25年后乳腺癌死亡多189例、冠心病死亡多380例、其他原因死亡多759例。

核心结论

  • 绝经前女性行卵巢切除后雌激素治疗使用不足与大量超额发病和死亡相关。

研究设计与样本

  • 研究开发了2个贝叶斯抽样马尔可夫状态转移模型,分别估算超额疾病发生率(发病率模型)和死亡率(死亡率模型)。
  • 两个模型的起始队列均为45至49岁因良性指征行双侧卵巢切除术加子宫切除术的女性,以5年间隔追踪25年。
  • 发病率模型估算乳腺癌、肺癌、结直肠癌、冠心病和卒中的超额发生率,死亡率模型估算乳腺癌、肺癌、冠心病和其他原因死亡导致的超额死亡率。
  • 模型比较当前雌激素治疗使用率与最佳(100%)使用率,计算每个模拟结局的平均差以确定超额疾病发生和死亡。

主要发现

  • 双侧卵巢切除加子宫切除术后25年,结直肠癌估计减少94例(95%置信区间,-158至-23)。
  • 术后25年,冠心病估计增加658例(95%置信区间,339至1025),卒中估计增加881例(95%置信区间,402至1483)。
  • 术后25年,乳腺癌死亡估计增加189例(95%置信区间,59至387),冠心病死亡估计增加380例(95%置信区间,114至792),其他原因死亡估计增加759例(95%置信区间,307至1527)。
  • 在将雌激素治疗使用定义为使用时长超过2年的敏感性分析中,上述差异增加超过2倍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Contrary to clinical guidelines, there has been a decrease over time in estrogen therapy use in premenopausal women undergoing bilateral oophorectomy for benign indications. OBJECTIVE: This study aimed to estimate the excess morbidity and mortality associated with current patterns of estrogen therapy use in women who undergo bilateral oophorectomy with hysterectomy for benign indications. STUDY DESIGN: We developed 2 Bayesian sampling Markov state-transition models to estimate the excess disease incidence (incidence model) and mortality (mortality model). The starting cohort for both models were women who had undergone bilateral oophorectomy with hysterectomy for benign indications at the age of 45 to 49 years. The models tracked outcomes in 5-year intervals for 25 years. The incidence model estimated excess incidence of breast cancer, lung cancer, colorectal cancer, coronary heart disease, and stroke, whereas the mortality model estimated excess mortality due to breast cancer, lung cancer, coronary heart disease, and all-other-cause mortality. The models compared current rates of estrogen therapy use with optimal (100%) use and calculated the mean difference in each simulated outcome to determine excess disease incidence and death. RESULTS: By 25 years after bilateral oophorectomy with hysterectomy, there were an estimated 94 (95% confidence interval, -158 to -23) fewer colorectal cancer cases, 658 (95% confidence interval, 339-1025) more coronary heart disease cases, and 881 (95% confidence interval, 402-1483) more stroke cases. By 25 years after bilateral oophorectomy with hysterectomy, there were an estimated 189 (95% confidence interval, 59-387) more breast cancer deaths, 380 (95% confidence interval, 114-792) more coronary heart disease deaths, and 759 (95% confidence interval, 307-1527) more all-other-cause deaths. In sensitivity analyses where we defined estrogen therapy use as a duration of >2 years of use, these differences increased >2-fold. CONCLUSION: Underuse of estrogen therapy in premenopausal women who undergo oophorectomy is associated with substantial excess morbidity and mortality.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Ferris JS, Suzuki Y, Prest MT, et al. Excess morbidity and mortality associated with underuse of estrogen replacement therapy in premenopausal women who undergo surgical menopause. Am J Obstet Gynecol. 2024. PMID: 38365100. doi:10.1016/j.ajog.2024.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。